학술논문

Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Document Type
Article
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p15-15, 235p
Subject
Language
ISSN
0732183X